Search results for "Blood Bactericidal Activity"

showing 8 items of 8 documents

Surface Components of Escherichia coli That Mediate Resistance to the Bactericidal Activities of Serum and Phagocytes

1985

Microorganisms that enter the animal body, either actively or passively, encounter a battery of nonspecific and specific chemical and cellular defenses whose role is to inactivate and eliminate foreign materials. Successful pathogens have the ability to avoid, resist, or inactivate these defenses for at least the period necessary for initiation of the disease process.

PhagocytebiologyPhagocytosisBlood Bactericidal Activitymedicine.disease_causebiology.organism_classificationEnterobacteriaceaeBacterial geneticsMicrobiologymedicine.anatomical_structuremedicineAnimal bodyEscherichia coliBacteria
researchProduct

An inherited deficiency of the third component of complement, C3, in guinea pigs

1986

Hereditary deficiency of the third component of complement, C3, is found very seldom in the human. C3 deficiency is associated with severe bacterial infections revealing the central role of C3 in complement activation via the classical or alternative pathway. We describe a new hereditary C3 deficiency in strain 2 guinea pigs. Serum from these animals had a markedly reduced lytic activity in a standard assay for complement-dependent, antibody-mediated cytotoxicity. In functional assays of individual components, the hemolytic activity of the components C4, C2, C5 and of factors B, D and H was in the normal range. The functional C3 titer, and similarly C3 antigenic activity in the serum of the…

Blood Bactericidal ActivityGuinea PigsImmunologyMacrophage-1 Antigenchemical and pharmacologic phenomenaBiologyHemolysisMajor Histocompatibility ComplexGuinea pigInbred strainAntigenIn vivoAnimalsImmunology and AllergyComplement ActivationRecombination GeneticComplement C3Molecular biologyIn vitroPedigreeReceptors ComplementComplement systemImmunologyAlternative complement pathwaybiology.proteinC3a receptorEuropean Journal of Immunology
researchProduct

Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci

2006

No vaccine is available for preventing infections by serogroup B Neisseria meningitidis (MenB), which accounts for a major portion of meningococcal cases in developed countries, because of the poor immunogenicity of the capsular polysaccharide (CP) even after protein conjugation. We have previously induced anticapsular antibodies by immunization with a single chain variable fragment (scFv), which mimics a protective CP epitope. This surrogate antigen, however, was ineffective at inducing serum bactericidal activity, an accepted marker of protection in humans. Serum bactericidal activity was consistently achieved by immunizing mice with the scFv-encoding gene. Immunization with vectors witho…

Blood Bactericidal ActivityImmunologyImmunoglobulin Variable Regionchemical and pharmacologic phenomenaBlood Bactericidal ActivityNeisseria meningitidis Serogroup BEpitopeArticleMicrobiologyDNA vaccinationMiceAntigenserogroup B Neisseria meningitidis; single chain variable fragment; DNA vaccinationChlorocebus aethiopsVaccines DNAImmunology and AllergyAnimalsRats WistarMice Inbred BALB CbiologyImmunogenicityArticlesVirologyAntibodies BacterialRatsBacterial vaccineMeningococcal InfectionsImmunizationAnimals NewbornBacterial VaccinesCOS Cellsbiology.proteinAntibody
researchProduct

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (Me…

2012

The present extension study, conducted in children originally vaccinated at 12–14 mo or 3–5 y of age, assessed antibody persistence and immune memory induced by an investigational tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT). In the original study, participants were randomized to receive one dose of MenACWY-TT or licensed age-appropriate meningococcal control vaccines. Fifteen months post-vaccination, all participants underwent serum sampling to evaluate antibody persistence and participants previously vaccinated as toddlers received a polysaccharide challenge to assess immune memory development.   Exploratory comparisons showed that (…

MaleBlood Bactericidal ActivityImmunologyPriming (immunology)Meningococcal VaccinesMeningococcal vaccineNeisseria meningitidismedicine.disease_causeimmune memoryPersistence (computer science)meningococcal vaccinechildrenConjugate vaccinemedicineHumansImmunology and AllergytoddlersPharmacologyMicrobial Viabilitybiologybusiness.industryTetanusNeisseria meningitidisToxoidInfantSpecial Focus Short Reportpersistencemedicine.diseaseAntibodies BacterialVirologyChild PreschoolImmunologybiology.proteinFemaleAntibodytetanus toxoidbusinessImmunologic MemoryHuman Vaccines & Immunotherapeutics
researchProduct

Role of iron, capsule, and toxins in the pathogenicity of Vibrio vulnificus biotype 2 for mice

1994

The virulence mechanisms of Vibrio vulnificus biotype 2 have been studied and compared with those of biotype 1 in mice as the experimental animals. Biotype 2 isolates from European eels were as virulent for mice as biotype 1 strains (50% lethal dose, about 10(5) CFU per mouse); a septicemic infection developed in less than 24 h. These strains had several properties in common with biotype 1 organisms including capsule expression, uptake of various iron sources, and production of exoproteins, whose role in mouse virulence has been demonstrated. We also discuss the implication of biotype 2 strains in human infections.

Blood Bactericidal ActivityIronImmunologyExotoxinsVirulenceVibrio vulnificusIn Vitro Techniquesmedicine.disease_causeMicrobiologyMicrobiologyMiceSpecies SpecificityVibrionaceaeVibrio InfectionsmedicineAnimalsHumansVibrioEelsVirulencebiologyToxinLethal dosebiology.organism_classificationVibrioBacterial Typing TechniquesInfectious DiseasesVibrio InfectionsParasitologyBacteriaResearch ArticleInfection and Immunity
researchProduct

Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes/macrophages

1997

The ability of Campylobacter jejuni to survive in monocytes after phagocytic uptake was tested in a new in vitro model using adherent macrophages derived from human peripheral monocytes. The cells were stimulated with cytokines before use to ensure full phagocytic and killing activity. The kinetics of uptake and killing of bacteria was followed for 72 h with 16 strains, including stool and blood isolates and laboratory adapted strains. Significant bacterial strain differences were not observed, but the viability of phagocytosed bacteria was dependent on the individual donating the macrophages. The majority of blood donors carried macrophages that killed phagocytosed Campylobacter within 24 …

LipopolysaccharidesMicrobiology (medical)Blood Bactericidal ActivityCellular immunityPhagocytosisImmunologyColony Count MicrobialBacteremiaIn Vitro TechniquesBiologymedicine.disease_causeCampylobacter jejuniMonocytesMicrobiologyCampylobacter jejuniPhagocytosisCampylobacter InfectionsmedicineHumansImmunology and AllergyMacrophagePhosphotransferases (Phosphate Group Acceptor)Superoxide DismutaseMacrophagesMonocyteCampylobacterGeneral MedicineCatalasebiology.organism_classificationEnteritisIn vitroKineticsmedicine.anatomical_structureMutationBacteriaMedical Microbiology and Immunology
researchProduct

Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals

1991

SUMMARYTwo sensitive sandwich ELISAs based on monoclonal antibodies directed to native C6 and C7 allowed the detection and quantitation of these complement proteins in 20 out of 37 serum samples from individuals who had previously been classified as deficient in these proteins as assessed by immunochemical and/or functional assays. Furthermore, serum from four C6-deficient and one combined C6-/C7-deficient individual showed an increase in the terminal complement complex (TCC) and a decrease in native C6 and C7 after complement activation as assayed by specific ELISAs. Despite their (incomplete) deficiencies, these individuals therefore possess functionally active terminal complement protein…

Blood Bactericidal Activitymedicine.drug_classImmunoblottingImmunologyEnzyme-Linked Immunosorbent AssayBiologyMonoclonal antibodyComplement Hemolytic Activity AssaySpecimen Handling03 medical and health sciences0302 clinical medicineTerminal complement complexImmunopathologymedicineHumansImmunology and AllergyComplement ActivationVolume concentration030304 developmental biology0303 health sciencesTemperatureZymosanAntibodies MonoclonalComplement deficiencyComplement C9Serum samplesmedicine.diseaseMolecular biologyComplement C7Complement C63. Good healthComplement (complexity)Complement systemImmunologyElectrophoresis Polyacrylamide GelResearch Article030215 immunologyClinical and Experimental Immunology
researchProduct

Isolation of Vibrio vulnificus Serovar E from Aquatic Habitats in Taiwan

1999

ABSTRACT The existence of strains of Vibrio vulnificus serovar E that are avirulent for eels is reported in this work. These isolates were recovered from water and oysters and differed from eel virulent strains in (i) fermentation and utilization of mannitol, (ii) ribotyping after Hin dIII digestion, and (iii) susceptibility to eel serum. Lipopolysaccharide of these strains lacked the highest molecular weight immunoreactive bands, which are probably involved in serum resistance.

SerotypeBlood Bactericidal Activityendocrine systemanimal structuresTaiwanVirulenceDeoxyribonuclease HindIIIVibrio vulnificusApplied Microbiology and BiotechnologyMicrobiologyRibotypingVibrionaceaeVibrio InfectionsAnimalsHumansSeawaterSerotypingVibrioEelsVirulenceEcologybiologybiology.organism_classificationOstreidaeVibrioBacterial Typing TechniquesOstreidaeEnvironmental and Public Health MicrobiologyVibrio InfectionsbacteriaWater MicrobiologyFood ScienceBiotechnologyApplied and Environmental Microbiology
researchProduct